See more : G Medical Innovations Holdings Ltd (GMVD) Income Statement Analysis – Financial Results
Complete financial analysis of Athira Pharma, Inc. (ATHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athira Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Daldrup & Söhne Aktiengesellschaft (4DS.DE) Income Statement Analysis – Financial Results
- Achiko AG (ACHKF) Income Statement Analysis – Financial Results
- Taronis Fuels, Inc. (TRNF) Income Statement Analysis – Financial Results
- Atrae, Inc. (6194.T) Income Statement Analysis – Financial Results
- Lakeshore Acquisition II Corp. (LBBB) Income Statement Analysis – Financial Results
Athira Pharma, Inc. (ATHA)
About Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 969.00K | 1.05M | 479.00K | 2.00M | 0.00 | 0.00 |
| Gross Profit | -969.00K | -1.05M | -479.00K | -2.00M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 93.79M | 61.46M | 42.79M | 13.29M | 3.79M | 3.59M |
| General & Administrative | 33.30M | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.30M | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Other Expenses | -1.63M | -5.16M | -8.84M | -1.32M | -754.00K | -164.00K |
| Operating Expenses | 125.47M | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Cost & Expenses | 125.47M | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Interest Income | 7.64M | 3.22M | 337.00K | 124.00K | 51.00K | 85.00K |
| Interest Expense | 0.00 | 24.32M | 3.00K | 367.00K | 346.00K | 9.00K |
| Depreciation & Amortization | 969.00K | 1.05M | 479.00K | 2.00M | 2.00K | 5.01M |
| EBITDA | -116.70M | -94.59M | -54.37M | -19.01M | -4.82M | -79.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -125.47M | -104.02M | -64.02M | -20.00M | -5.45M | -5.01M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.79M | 8.38M | 9.17M | 40.00K | 288.00K | -88.00K |
| Income Before Tax | -117.67M | -95.64M | -54.85M | -19.96M | -5.16M | -5.10M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.38M | -479.00K | -1.32M | -459.00K | -76.00K |
| Net Income | -117.67M | -87.26M | -54.37M | -18.63M | -4.70M | -5.10M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.10 | -2.31 | -1.47 | -0.57 | -0.14 | -0.82 |
| EPS Diluted | -3.09 | -2.31 | -1.47 | -0.57 | -0.14 | -0.82 |
| Weighted Avg Shares Out | 38.02M | 37.73M | 36.92M | 32.49M | 32.62M | 6.19M |
| Weighted Avg Shares Out (Dil) | 38.02M | 37.73M | 36.92M | 32.49M | 32.62M | 6.19M |
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in a panel...
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA)
Athira Pharma, Inc. (ATHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal...
Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Athira Pharma, Inc. (ATHA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the...
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
Completed end of Phase 2 meeting and continu e d engagement with U.S. Food and Drug Administration Appointed Andrew Gengos as Chief Financial Officer and Chief Business Officer Maintains strong balance sheet to support innovative clinical development pipeline in neurodegenerative...
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease
New preclinical data demonstrate neuroprotective effects of fosgonimeton in models of amyloid-ß -mediated toxicity
Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023
Three poster presentations to highlight clinical and preclinical data across Athira's pipeline of neuroprotective therapeutic candidates Three poster presentations to highlight clinical and preclinical data across Athira's pipeline of neuroprotective therapeutic candidates
Athira Pharma to Participate in Upcoming June Conferences
BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming...
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
Veteran biopharmaceutical executive brings over 30 years of financial, corporate strategy, transactional and business development experience Veteran biopharmaceutical executive brings over 30 years of financial, corporate strategy, transactional and business development experience
Athira Pharma to Participate in Upcoming May Investor Conferences
BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will participate in the following upcoming investor...
Source: https://incomestatements.info
Category: Stock Reports